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In contrast to canonical phage endolysins, which require holin-mediated disruption of the membrane to gain
access to attack the cell wall, signal anchor release (SAR) endolysins are secreted by the host sec system, where
they accumulate in an inactive form tethered to the membrane by their N-terminal SAR domains. SAR
endolysins become activated by various mechanisms upon release from the membrane. In its inactive form, the
prototype SAR endolysin, LyzP1, of coliphage P1, has an active-site Cys covalently blocked by a disulfide bond;
activation involves a disulfide bond isomerization driven by a thiol in the newly released SAR domain,
unblocking the active-site Cys. Here, we report that Lyz103, the endolysin of Erwinia phage ERA103, is also a
SAR endolysin. Although Lyz103 does not have a catalytic Cys, genetic evidence suggests that it also is activated
by a thiol-disulfide isomerization triggered by a thiol in the SAR domain. In this case, the inhibitory disulfide
in nascent Lyz103 is formed between cysteine residues flanking a catalytic glutamate, caging the active site.
Thus, LyzP1 and Lyz103 define subclasses of SAR endolysins that differ in the nature of their inhibitory
disulfide, and Lyz103 is the first enzyme found to be regulated by disulfide bond caging of its active site.
In infections by double-stranded DNA phages, host lysis
requires degradation of the peptidoglycan by a phage-encoded
endolysin (17). By far the most intensively studied endolysin is
the T4 lysozyme E (EC 3.2.1.17), which attacks the glycosidic
bonds between GlcNAc and MurNAc in the murein (1). Dur-
ing the latent period, canonical endolysins are produced as
fully active enzymes sequestered in the cytoplasm, thereby
preventing premature lysis. Another phage protein, the holin,
terminates the infection cycle by suddenly forming extremely
large, nonspecific holes in the membrane that allow the endo-
lysin to escape and attack the murein layer. Recently, studies of
the lysis system of bacteriophage P1 have revealed that phage-
encoded endolysins are not always dependent upon holins for
export (19, 20). Although it is an ortholog of T4 E, the P1
lysozyme, LyzP1, is translocated across the cytoplasmic mem-
brane by the host sec system by virtue of an N-terminal trans-
membrane domain (TMD) that is absent in E (Fig. 1A). Since
this transmembrane domain is not removed by signal pepti-
dase, nascent LyzP1 remains tethered to the membrane with its
catalytic residues already present in the periplasm. The LyzP1
TMD exits the membrane and becomes part of the soluble,
periplasmic form of the protein, either at a low spontaneous
rate or, more efficiently, when the holin triggers to depolarize
the membrane (11). Because of the unique ability to direct
sec-mediated export and membrane insertion and to support
release into the periplasm from the bilayer, the TMD of LyzP1
was designated a signal anchor release (SAR) domain. More
recently, other SAR endolysins have been identified and char-
acterized (15, 16). In fact, bioinformatic analysis suggests that
most members of the T4 lysozyme family, recognizable by the
Glu-8aa-(Asp/Cys)-5aa-Thr catalytic triad (Fig. 1A), are SAR
endolysins (43 of 58 entries in the GenBank protein database)
(16).
Since the lyzP1 gene is expressed well before progeny P1
phage have been assembled, there must be a mechanism to
ensure that the membrane-tethered form of the protein is kept
enzymatically inactive so that premature lysis is avoided. A key
to the regulation of LyzP1 is the fact that the P1 enzyme has a
catalytic cysteine residue, Cys51 (Fig. 1A), in the central posi-
tion of the catalytic triad, in contrast to E and most of its
orthologs, which have an Asp residue in this position (20).
Genetic, biochemical, and structural analysis of LyzP1 demon-
strated that the membrane-tethered form is inactive for two
reasons: first, the entire catalytic domain is misfolded, so the
active-site cleft is completely missing, and second, the catalytic
Cys51 is covalently occupied in a disulfide bond with another
Cys at position 44. This led to a model for activation in which
a thiol (Cys13) present in the SAR domain becomes unmasked
upon membrane release and triggers a disulfide bond isomer-
ization, liberating the thiol of the catalytic Cys51. This model
was confirmed by crystal structures showing the alternative
disulfide linkages in the inactive and active forms of LyzP1 (19).
LyzP1 became the prototype of a class of SAR endolysins
recognizable by the Asp3Cys substitution in the catalytic triad
and the presence of activating Cys in the N-terminal SAR
domain. However, most SAR endolysins belong to a second
major class, represented by R21, the endolysin of the lambdoid
phage 21 (20). These enzymes have the canonical Glu-8aa-
Asp-5aa-Thr catalytic triad and no Cys residue in the SAR
domain. Instead, genetic and structural analysis revealed that
in the inactive form, the catalytic domain has nearly the correct
fold, except for a displacement of the active-site Glu, but is
subject to steric hindrance by the proximity of the bilayer in
which the SAR domain is embedded. In the soluble, active
form, the SAR domain of R21 has refolded into the main body
of the enzyme, providing a floor to the active site and reposi-
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tioning the catalytic glutamate to its proper place (16). Thus,
the R21 regulatory scheme is markedly different from that of
LyzP1, where the released SAR domain provides only the free
thiol for the disulfide bond rearrangement and makes few
contacts with the enzyme itself.
Here, we examine the regulation of the endolysin Lyz103 of
the Erwinia amylovora phage ERA103 (GenBank accession no.
EF160123), which seems to have characteristics of both of
these major classes: it has a Cys residue in an N-terminal
hydrophobic sequence but retains the canonical Asp residue in
the catalytic triad. The results are discussed in terms of a
model for SAR-dependent disulfide bond isomerization dis-
tinct from that of LyzP1 and its homologs but which neverthe-
less confers a covalent constraint on premature activation of
the muralytic activity.
MATERIALS AND METHODS
Bacterial strains and growth conditions. The Escherichia coli strains XL1-Blue
and MC4100 and the MG1655 fhuA lacIq lacY mutant strain have been de-
scribed previously (13, 16). Standard conditions for the growth of cultures and
the monitoring of lysis kinetics have also been described previously (3, 13). All
bacterial cultures were grown in standard LB medium, supplemented with 100
g/ml ampicillin when appropriate. When indicated, isopropyl--D-thiogalacto-
pyranoside (IPTG), dinitrophenol (DNP), and dithiothreitol (DTT) were added
to achieve final concentrations of 1 mM, 10 mM, and 1 mM, respectively.
DNA procedures and plasmid construction. Procedures for the isolation of
plasmid DNA, DNA amplification by PCR, PCR product purification, DNA
transformation, site-directed mutagenesis, and DNA sequencing have been pre-
viously described (5, 12, 14). The construction of the plasmid pLyzP1, a derivative
of pJF118EH, has been described previously (4, 20). The plasmid pLyz103 was
constructed by amplifying and inserting lyz103 between the EcoRI and HindIII
restriction sites of pJF118EH. Similarly, the construct pETLyz103 was con-
structed by amplifying lyz103 and inserting it between XbaI and BamHI of
pET11a (Novagen). For overexpression purposes, the inactive allele
lyz103(D52N) was used. Derivative alleles of lyz103 and lyzP1 were made using
site-directed mutagenesis. For detection and purification purposes, the lyz103
allele was modified to encode an oligo-histidine tag (Gly2His6Gly2) appended to
Met178 by site-directed mutagenesis. All purified proteins cited in this work refer
to the oligo-histidine-tagged versions.
SDS-PAGE and Western blotting. SDS-PAGE, Western blotting, and immu-
nodetection experiments were performed as previously described (5). Antiserum
against LyzP1 was prepared in chickens by Aves Labs (Tigard, OR) and was used
at a dilution of 1:1,000. A mouse monoclonal antibody against the oligo-histidine
epitope tag was purchased from Amersham and was used at a dilution of 1:3,000.
Horseradish peroxidase-conjugated secondary antibodies against chicken IgY
were purchased from Aves Labs and were used at a 1:2,000 dilution for colori-
metric detection and a 1:300,000 dilution for chemiluminescent detection. The
anti-mouse IgG horseradish peroxidase-conjugated secondary antibody was sup-
plied with the SuperSignal chemiluminescence kit (Pierce) and was used at a
1:5,000 dilution. Blots were developed using the chromogenic substrate 4-chloro-
1-naphthol (Sigma) or with the West Femto SuperSignal chemiluminescence kit
(Pierce). Chemiluminescent signal was detected using a Bio-Rad ChemiDoc XRS.
Subcellular fractionation. Soluble or membrane localization was determined
as described previously (16, 20). Briefly, 25 ml of an induced culture was col-
lected by centrifugation at 5,000  g in a Sorvall Superspeed RC2-B centrifuge
and resuspended in 2 ml of French press buffer (0.1 M sodium phosphate, 0.1 M
KCl, 5 mM EDTA, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride,
pH 7.0). Cells were disrupted by passage through a French pressure cell (Spec-
tronic Instruments, Rochester, NY) at 16,000 lb/in2. The membrane and soluble
fractions were separated by centrifugation at 100,000  g in a Beckman TL-100
ultracentrifuge for 60 min. Equivalent amounts of each fraction were examined
by SDS-PAGE and Western blotting as described above.
Sulfhydryl modification using PEG-OPSS. To detect the presence of free
cysteines in SAR endolysins, a 5-ml sample of a culture induced in logarithmic
phase for 25 min was precipitated by trichloroacetic acid (TCA). The pellet was
resuspended in 1 ml of PEGylation buffer (500 mM Tris [pH 7.0], 1% SDS, 1 mM
EDTA), and mPEG-OPSS (Nektar Transforming Therapeutics, Huntsville, AL)
(8) was added to produce a final concentration of 3 M. The mixture was
incubated for 30 min at room temperature and then precipitated by the addition
of 1 ml of ice-cold acetone. The samples were held at 20°C for 10 min, after
which the precipitate was collected by centrifugation at 18,000  g at 4°C for 15
min. The pellets were air dried, resuspended in nonreducing SDS sample buffer,
and examined by SDS-PAGE and Western blotting. All samples were run with
controls that had not been exposed to PEG-OPSS.
Lyz103 expression and purification. Since wild-type Lyz103 lyses cells rapidly
when overexpressed, the enzyme activity was abolished by replacing the catalytic
Asp with Asn. Hence, all purified Lyz103 cited in this work refers to
Lyz103(D52N). pET lyz103(D52N) cHis was transformed into BL21(DE3) cells
(Invitrogen) harboring pLysS, and fresh transformants were cultured and in-
duced for 1 h at 30°C. Cells were collected at 4,000 rpm for 30 min at 4°C in a
Sorvall RC-3B centrifuge and resuspended in Lyz103 buffer (20 mM Tris-HCl
[pH 8], 100 mM NaCl). Protease inhibitor cocktail for His-tagged protein
FIG. 1. Sequence alignments. (A) Alignment of T4E, LyzP1, and Lyz103. Catalytic residues are highlighted in blue, Cys residues in pink, and
SAR domains in yellow. Locations of Leu substitutions are indicated below the corresponding Gly residue (green). Inactivating/caging disulfides
for LyzP1 and Lyz103, respectively, are shown as arrows connected with a black line above the participating Cys residues. Disulfides resulting from
isomerization are shown below the participating Cys residues as arrows connected with a brown line. (B) Alignments of LyzP13103 and Lyz1033P1
conversion mutants. Catalytic residues are highlighted in blue, Cys residues in pink, and SAR domains in yellow. Locations of Cys substitutions
are indicated below the corresponding residue.
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(Sigma) was added as per the manufacturer’s instructions, and cells were lysed by
passage through a French pressure cell (Spectronic Instruments, Rochester, NY)
at 20,000 lb/in2. After unlysed cells and debris were removed, the lysate was
filtered through a 0.2-m syringe filter. The cleared lysate was then applied to
Talon metal affinity resin (Clontech). Protein was eluted in elution buffer (20
mM Tris-HCl, 100 mM NaCl, 500 mM imidazole, pH 8) and was used with no
further purification.
CDAP cleavage. Purified Lyz103(D52N) was precipitated and resuspended in
100 l CDAP (1-cyano-4-dimethylaminopyridinium tetrafluoroborate) buffer (4
M guanidine-HCl, 0.1 M citrate, pH 3). CDAP (Sigma), prepared fresh in CDAP
buffer, was added in 1,000-fold molar excess and was incubated at room tem-
perature for 15 min. NH4OH (EMD Chemicals) was added to achieve a 1 M final
concentration, and the mixture was incubated at room temperature for 3 h (10,
18). Total protein was precipitated by the addition of 1 ml of ice-cold ethanol and
incubated overnight at 20°C. Samples were pelleted, dried, and resuspended in
sample loading buffer with or without 5% -mercaptoethanol, as indicated.
Equivalent amounts were analyzed by SDS-PAGE and Western blotting.
RESULTS AND DISCUSSION
The lysozyme from bacteriophage ERA103 has an N-termi-
nal SAR domain. We first wished to confirm that the N-termi-
nal hydrophobic domain of Lyz103 is a SAR domain. Induction
of lyz103 resulted in lysis of Escherichia coli, even without a
holin gene present, indicating a spontaneous release from the
membrane and consequent lysis (Fig. 2A). Moreover, like
LyzP1, Lyz103 was found in both the soluble and membrane
fractions of cells (Fig. 3A). For both proteins, the membrane-
associated and soluble forms migrate identically in SDS-
PAGE, indicating that the latter is not derived by the proteo-
lytic cleavage of the former. Additionally, energy poisons such
as DNP accelerated the lysis of cultures expressing lyz103 (Fig.
2A), indicating that the collapse of the proton motive force
facilitates the membrane release and activation of Lyz103, as it
does for LyzP1 (20). The SAR domains characterized in LyzP1
and R21 differ from conventional TMDs in that they have a
high content of weakly hydrophobic and uncharged polar res-
idues, such as Ala, Gly, and Ser (20). In both cases, substitution
of Leu residues for Gly residues (3 in LyzP1 [Fig. 2, 3C] and 2
in R21 [16]) in the SAR domain blocked the release from the
membrane and host lysis. The same molecular and cellular
phenotype was observed for Lyz103 when Gly residues at po-
sitions 9 and 10 in the SAR domain were converted to Leu
(Fig. 2C, 3D). These results are consistent with the require-
ment for the SAR domain to exit the membrane, liberating the
thiol in the SAR domain to attack the inhibitory disulfide.
Thus, Lyz103 is the third SAR endolysin to be characterized in
terms of its physiological and topological characteristics. The
predicted amino acid sequence of Lyz103 is identical to that of
the lysozyme from bacteriophage Ea1h. Thus, the puzzling
lethality observed when lyzEa1h was expressed in the absence
of its holin (6, 7) is due to the fact that, as a SAR endolysin, it
reaches the periplasm by a holin-independent mechanism.
The activity of Lyz103 is regulated by a disulfide “cage.”
Lyz103, like T4 E but unlike LyzP1, has an Asp residue as the
middle component of its catalytic triad and thus is not regu-
lated by covalent blocking of an active-site Cys (Fig. 1A).
Nonetheless, the N-terminal catalytic domain of Lyz103 con-
tains three Cys residues (Cys12, Cys42, Cys45), including one in
the SAR domain, suggesting that it might exist in two isomeric
forms differing in the arrangement of intramolecular disulfide
bonds, as documented for LyzP1. To test this possibility, the
C12S mutant of Lyz103 was tested for function. This mutant
was found to be lytically inactive (Fig. 2B), although it was
released from the inner membrane as efficiently as the wild-
type protein (Fig. 3B). Moreover, the addition of the reducing
agent, dithiothreitol, to cells expressing the C12S mutant
resulted in lysis (Fig. 2B). Finally, the triple mutant,
Lyz103(C12,42,45S), was found to be lytically active (Fig. 2B).
The behavior of these two mutants is consistent with the model
that nascent Lyz103 is inactive because of an inhibitory Cys42-
Cys45 disulfide that is disrupted by Cys12 after the release of
the SAR domain from the membrane. Since the inhibitory
disulfide predicted to exist in nascent Lyz103 involves cysteines
that flank an essential catalytic residue (Fig. 1A), we refer to it
as a “caging” disulfide to distinguish it from the inactivating
disulfide present in LyzP1. It is of interest to note that a similar
inactive, disulfide-caged form of T4 gpe was constructed 21
FIG. 2. In each experiment, cultures of XL1-Blue containing LyzP1
or Lyz103 in pJF118EH were induced at time zero. The optical density
of the culture was followed as a function of time in minutes. (A) Ex-
pression of Lyz103 lyses the cell independently of a holin. E, LyzP1; f,
Lyz103; , Lyz103 plus 10 mM DNP 20 min (arrow) after induction.
(B) Lysis by Lyz103 is dependent on the SAR domain Cys. f,
Lyz103(C12S); , Lyz103(C12S) plus 1 mM DTT at 36 min (arrow)
after induction; }, Lyz103(C12,42,45S). (C) LyzP1 and Lyz103 can be
locked into the membrane by Leu titration into the SAR domain. E,
Lyz103(G9,10L); f, LyzP1(G8,9,10L). (D) LyzP1 and Lyz103 can be
interconverted. LyzP13103 was achieved by two amino acid mutations:
A41C and C51D (F). Lyz1033P1 was achieved by two amino acid
mutations: C42S and D52C (). E, LyzP13103(C13S); f,
LyzP13103(C13S) plus 1 mM DTT at 45 min (arrow); },
Lyz1033P1(C12S). (E) There is optimal positioning of the SAR domain
Cys. Cys substitutions are labeled adjacent to their respective
curves. F, LyzP13103(G9C); f, LyzP13103(G10C); E,
LyzP13103(A11C); }, LyzP13103(I12C); ‚, LyzP13103; ,
LyzP13103(A14C); , LyzP13103(I15C); Œ, LyzP13103(A16C).
(F) The placement of the caging disulfide is stringent. F,
LyzP1(I38C, C51D); E, LyzP1(G39C, C51D); f, LyzP1(N40C,
C51D); , LyzP1(C13S, I38C, C51D); }, LyzP1(C13S, G39C,
C51D); , LyzP1(C13S, N40C, C51D).
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years ago (9). In this form of T4 gpe, the active-site residues
are unaltered but an engineered disulfide occludes the active
site. As shown here with Lyz103 and earlier with LyzP1, the
disulfide-caged form of T4 gpe could be activated by reducing
agents.
Disulfide bond isomerization. The results presented above
indicate that the Cys42-Cys45 disulfide cages the catalytic Glu43
in inactive Lyz103 and that the Cys12 thiol from the SAR do-
main is required for activation, but the results do not reveal
whether one of the two Cys residues flanking Glu43 partici-
pates in a disulfide exchange with Cys12 and, if so, which one
(Fig. 1A). To address this question, we used the sulfhydryl
cyanylation reagent 1-cyano-4-dimethylaminopyridinium tet-
rafluoroborate (CDAP). Treatment of a CDAP-cyanylated
protein with a strong base cleaves the protein on the N-termi-
nal side of the cyanylated Cys, leaving an N-terminal 2-imi-
nothiazolidine-4-carboxylyl (itz) modification on the C-termi-
nal product (10, 18). If activated Lyz103 has a disulfide between
Cys12 and Cys42, Cys45 will be open for CDAP modification
and subsequent cleavage would create two polypeptide frag-
ments which could be resolved from uncleaved protein without
the presence of a reducing agent (Fig. 4A). In contrast, a
linkage between Cys12 and Cys45 will leave Cys42 open for
modification. In this case, cleavage with a strong base would
result in polypeptide fragments that were still covalently linked
and which would require treatment with a reducing agent to be
resolved from uncleaved material (Fig. 4B). When purified
Lyz103 was subjected to CDAP treatment and alkaline cleavage
and analyzed by Western blotting with anti-oligo-histidine tag
antibodies, a polypeptide product of an appropriate size (16
kDa) could be resolved from uncleaved protein (20 kDa) by
SDS-PAGE without a reducing agent (Fig. 4C). The yield of
cleavage product was low, approximately 10 to 15% of total
protein. However, treatment of the CDAP-modified product
with PEG-OPSS revealed that 60% of the protein was cya-
nylated by CDAP and therefore unPEGylated (data not
shown). This indicates that the cleavage reaction, rather than
sulfhydryl accessibility, was limiting, presumably due to the
high incidence of the competing -elimination reaction, as
noted elsewhere (18). Taken together, these results indicate
that the Lyz103-activating linkage resulting from the disulfide
bond isomerization after SAR extraction is between Cys12 and
Cys42 rather than between Cys12 and Cys45, as predicted from
the LyzP1 and Lyz103 sequence alignments (Fig. 1A). Thus, the
position of the disulfide bond exchange is not conserved.
The LyzP1 and Lyz103 regulatory schemes are interconvert-
ible. Comparing the crystal structures of the active and an
inactive form of LyzP1 demonstrates that much of the N ter-
minus of the protein is capable of adopting markedly different
conformations depending upon the placement of a single in-
tramolecular disulfide (19). To explore the structural mallea-
bility of the N-terminal catalytic domain of LyzP1 (Glu42, Cys51,
and Thr57), we attempted to convert LyzP1, in which the inac-
tivating disulfide covalently blocks a catalytic Cys, into a
Lyz103-type endolysin, with a caging disulfide sequestering a
catalytic Glu, by introducing the A41C and C51D mutations
(Fig. 1B, Table 1). This mutant, LyzP13103, was found to be
lytically active, although lysis was delayed and more gradual
compared with that of the wild-type enzyme (Fig. 2D). As
seen with LyzP1, removal of the SAR domain Cys in
LyzP13103(C13S) rendered the enzyme dependent upon the
addition of an exogenous reductant (Fig. 2D). Moreover, in-
troducing the C42S and D52C mutations into Lyz103 (Fig. 1B)
converted the enzyme into a LyzP1-type endolysin that still
required the presence of the Cys residue in its SAR domain for
lytic function (Fig. 2D). Thus, with regard to the nature of the
inhibitory disulfide and the use of a catalytic Cys or Asp, LyzP1
and Lyz103 are fully interconvertible. Since we had polyclonal
antibodies at hand for LyzP1 which were much more efficient
than the antibodies against the oligo-histidine tag for Lyz103,
the LyzP13103 construct was selected for further analysis.
Optimal positioning of the SAR Cys residue. Since we had
previously demonstrated that the in vivo activity of LyzP1 de-
FIG. 3. The endolysins of bacteriophages P1 and ERA103 are SAR
endolysins. For all panels, the total protein is represented by lane 1, the
soluble protein fraction is represented by lane 2, and the membrane
fraction is represented by lane 3. (A) Lyz103 exists in the soluble and
membrane fractions of the cell. (B) Lyz103(C12S) displays a nonlytic
phenotype but is released from the cytoplasmic membrane as effi-
ciently as the wild-type protein. (C) LyzP1 can be confined to the inner
membrane by replacing three glycines (residues 8 to 10) with leucine
residues. (D) Lyz103 can be confined to the inner membrane by replac-
ing two glycines (residues 9 and 10) with leucine residues.
FIG. 4. Analysis of the cage-relieving disulfide. Purified
Lyz103(D52N) cHis was subjected to CDAP cyanylation and alkaline
cleavage. Proteins were resolved by SDS-PAGE with and without a
reducing agent, as indicated. (A) A cage-relieving disulfide between
Cys12 and Cys42 will allow Cys45 to be modified by CDAP. Cleavage of
this protein results in a C-terminal cleavage fragment that is resolvable
without the addition of a reducing agent (-Me). (B) A cage-relieving
disulfide between Cys12 and Cys45 results in a cleavage product that is
resolved only upon the addition of -Me. (C) Treatment of
Lyz103(D52N) with 1,000-fold molar excess of CDAP reagent resulted
in a resolvable C-terminal cleavage product (16 kDa), indicating the
formation of a Cys12-Cys42 disulfide.
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pended upon the placement of the Cys13 residue in its SAR
domain (19), we reasoned that the poor lytic profile obtained
with the LyzP13103 protein might be due to the suboptimal
positioning of this critical residue. To test this notion, con-
structs were generated in which the Cys13 residue in the SAR
domain was moved to eight new positions, four in each direc-
tion, from the parental site in the context of LyzP13103. The
results validated the hypothesis, in that earlier and sharper lysis
profiles were obtained with a Cys occupying positions 12, 10,
14, and 16, in order of apparent lytic activity (Fig. 2E). This
pattern is different from that observed using the equivalent
substitutions in LyzP1, where the Cys13 form is the most active
and moving the thiol to position 12 eliminated the ability to
activate (19). These differences could be due to a combination
of factors, since the activation of LyzP1 involves major struc-
tural changes within the N-terminal catalytic domain and all of
the mutations necessary to convert LyzP1 into LyzP13103 and
its derivatives occurred within this domain.
Strict positional requirement for the inhibitory disulfide
cage. We next determined the effect of moving the position of
the first Cys (Cys41) of the inhibitory disulfide cage in
LyzP13103 toward the N terminus of the protein (Fig. 1B). All
three variants (N40C, G39C, and I38C) tested were lytic (Fig.
2F). Surprisingly, the lethality of these proteins was not com-
pletely dependent upon the presence of a Cys in the SAR
domain, as lysis still occurs, although much later and more
gradually (Fig. 2F). The simplest explanation for this finding is
that disulfides between Cys38, Cys39, or Cys40 and Cys44 do not
effectively cage the active-site glutamate. We directly assessed
the status of the cysteines in LyzP13103, LyzP13103(C13S), and
LyzP1(C13S, I38C, C51D), the most lytically active cage
mutant, by testing their susceptibility to modification by PEG-
OPSS. PEG-OPSS has a PEG 5000 moiety affixed to an or-
thopyridyl disulfide. When reacted with a free sulfhydryl, PEG-
OPSS will covalently bind and will shift the apparent molecular
weight of the protein (8). As expected, the active endolysin,
LyzP13103, was found to have a single free cysteine (Cys13),
while the inactive enzyme, LyzP13103(C13S), had none (Fig. 5).
The lytically active LyzP1(C13S, I38C, C51D) protein was not
modified with PEG-OPSS, indicating that all six of its cysteine
residues were present in disulfide linkages. Thus, while the
Cys38-Cys44 disulfide forms, it is not inhibitory.
Conclusion. Two modes of SAR endolysin negative regula-
tion have previously been experimentally established. The first
is that of an inactivating disulfide involving a catalytic Cys, as is
present in LyzP1 (19); the presence of the disulfide not only
precludes participation of the catalytic Cys but also stabilizes a
drastically misfolded N-terminal domain. The second mode
was found in R21, in which the inactive protein has more subtle
folding defects, but the active site is compromised by the prox-
imity of the membrane to which it is tethered by the embedded
SAR domain. The results presented here demonstrate that
Lyz103 represents a third distinct mode of SAR endolysin reg-
ulation: disulfide bond caging of the active site in the inactive
form of the enzyme (Fig. 6). Despite these differences in the
regulatory mode, however, the two proteins appear to be com-
pletely interconvertible by simply repositioning the regulatory
Cys residues and adjusting the position of the activating Cys
residue in the SAR domain. These findings serve to emphasize
both the plasticity of the SAR regulatory system and the im-
portance of regulating the timing of lysis in the infection cycle.
Finally, it should be noted that another instance of disulfide
FIG. 5. Assessment of the status of cysteine residues. LyzP13103 is
an active endolysin and has a single free sulfhydryl. It is modified by
PEG-OPSS (lane 1). LyzP13103(C13S) has no free cysteine residues
and is not modified by PEG-OPSS (lane 2). LyzP1(C13S, I38C, C51D)
is an active endolysin despite the presence of the caging disulfide (lane
3). As confirmation of the presence of this disulfide, the protein is not
modified by PEG-OPSS, indicating that all of its cysteines are in
disulfide bonds. Lanes 1 to 6 contain unPEGylated LyzP13103,
LyzP1(C13S), and LyzP1(C13S, I38C, C51D), respectively.
TABLE 1. Catalytic triads, cysteines participating in enzyme regulation, mutations required for the LyzP13103 and Lyz1033P1 conversions, and
approximate lysis times of LyzP1, Lyz103, LyzP13103, and Lyz1033P1
a
Lysozyme Catalytic triad Regulating cysteines Conversionmutations
Lysis time
(min)
LyzP1 E42, C51, T57 C13 (SAR), C44, C51 (catalytic) NA 15
Lyz103 E43, D52, T58 C12 (SAR), C42, C44 NA 35
LyzP13103 E42, D51, T57 C13 (SAR), C41, C44 A41C, C51D 50
Lyz1033P1 E43, C52, T58 C12 (SAR), C44, C52 (catalytic) C42S, D52C 45
a Cysteines located in the SAR domain and catalytic cysteines are indicated. NA, not applicable.
FIG. 6. Model for Lyz103 activation. In its inactive form, Lyz103 is
tethered to the charged cytoplasmic membrane. A caging disulfide
exists between Cys42 (blue) and Cys45 (green) that sequesters the
catalytic Glu from the remaining members of the catalytic triad. Upon
SAR domain (hatched bar) release from the membrane, the SAR
thiol, Cys12 (red), attacks the caging disulfide at Cys42, forming a
cage-relieving disulfide. The catalytic Glu is released from the cage and
can form the catalytic cleft.
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bonding affecting the steric blockage of an enzyme active site
has been reported in NADP-malate dehydrogenase from chlo-
roplasts (2). In this case, intramolecular steric regulation is
achieved when a C-terminal helix, positioned and stabilized by
a disulfide bond, occupies the active site and forms hydrogen
bonds with catalytic residues. The negative regulation is re-
leased when the conserved disulfide is reduced by thioredoxin
in response to light stimulation. A key difference is that the
Lyz103 activation, driven by the release of the SAR domain
from the bilayer, is almost certainly irreversible, and thus the
stabilities of the inactive and active states are unlikely to be
comparable.
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